Introduction
Since I first wrote about Atara Biotherapeutics (ATRA) in October 2019, its share price has gone through a rollercoaster ride, reflecting the binary nature of investing in clinical-stage biotech companies. Share prices went as high up to over $17, before dropping by over 50% following the stock market crash due to uncertainty over the COVID-19 pandemic.
Since my first article, Atara’s new CEO, Pascal Touchon, has settled in well and refocused the company's strategic priorities. In this article, I revisit its prospects and reaffirm my bullish views on the company.